Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Terumo ( (JP:4543) ) has shared an update.
Terumo reported solid growth for the nine months ended Dec. 31, 2025, with revenue rising 7.7% year on year to ¥831.6 billion and operating profit up 8.5% to ¥144.9 billion, while profit attributable to owners of the parent climbed 11.1% and basic earnings per share increased to ¥74.27. The company’s balance sheet expanded with total assets reaching ¥2.26 trillion though the equity ratio declined, and it maintained guidance for fiscal 2025, targeting 6.9% revenue growth and a 16.3% rise in full-year profit alongside a planned dividend increase to ¥30 per share.
The most recent analyst rating on (JP:4543) stock is a Hold with a Yen2229.00 price target. To see the full list of analyst forecasts on Terumo stock, see the JP:4543 Stock Forecast page.
More about Terumo
Terumo Corporation is a Japan-based medical technology company listed on the Tokyo Stock Exchange, focusing on medical devices and healthcare solutions. Its portfolio spans vascular intervention systems, cardiac and cardiovascular products, and blood management and hospital equipment, serving hospitals and healthcare providers globally.
Average Trading Volume: 5,278,110
Technical Sentiment Signal: Hold
Current Market Cap: Yen3120.5B
Learn more about 4543 stock on TipRanks’ Stock Analysis page.